These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 25870982)
1. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982 [TBL] [Abstract][Full Text] [Related]
2. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. Ciaranello AL; Lockman S; Freedberg KA; Hughes M; Chu J; Currier J; Wood R; Holmes CB; Pillay S; Conradie F; McIntyre J; Losina E; Walensky RP; AIDS; 2011 Feb; 25(4):479-92. PubMed ID: 21293199 [TBL] [Abstract][Full Text] [Related]
3. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586 [TBL] [Abstract][Full Text] [Related]
4. The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa. Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA PLoS One; 2013; 8(2):e54435. PubMed ID: 23457450 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Simpson KN; Luo MP; Chumney EC; King MS; Brun S Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581 [TBL] [Abstract][Full Text] [Related]
6. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527 [TBL] [Abstract][Full Text] [Related]
7. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011. Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716 [TBL] [Abstract][Full Text] [Related]
8. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings? Ahmed BS; Phelps BR; Reuben EB; Ferris RE Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443 [TBL] [Abstract][Full Text] [Related]
9. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747 [TBL] [Abstract][Full Text] [Related]
12. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Simpson KN; Baran RW; Kirbach SE; Dietz B Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Simpson KN; Jones WJ; Rajagopalan R; Dietz B Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538 [TBL] [Abstract][Full Text] [Related]
14. Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis. Dunning L; Gandhi AR; Penazzato M; Soeteman DI; Revill P; Frank S; Phillips A; Dugdale C; Abrams E; Weinstein MC; Newell ML; Collins IJ; Doherty M; Vojnov L; Fassinou Ekouévi P; Myer L; Mushavi A; Freedberg KA; Ciaranello AL J Int AIDS Soc; 2021 Jan; 24(1):e25651. PubMed ID: 33474817 [TBL] [Abstract][Full Text] [Related]
15. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P; Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305 [TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210 [TBL] [Abstract][Full Text] [Related]
17. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. Dugdale CM; Phillips TK; Myer L; Hyle EP; Brittain K; Freedberg KA; Cunnama L; Walensky RP; Zerbe A; Weinstein MC; Abrams EJ; Ciaranello AL; PLoS One; 2019; 14(11):e0225104. PubMed ID: 31730630 [TBL] [Abstract][Full Text] [Related]
19. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy. Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]